Products - Oesophageal cancer | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 35 products

Date | Title

Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (TA1046)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 March 2025
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal) (TA1024)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 December 2024
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 August 2024
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
29 August 2024
Published:
20 October 2021
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 June 2024
Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
23 June 2015
Oesophago-gastric cancer: assessment and management in adults (NG83)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
4 July 2023
Published:
24 January 2018
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 April 2023
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management (NG231)
Product type:
Guidance
Programme:
NICE guideline
Published:
8 February 2023
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 February 2023
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 January 2023
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments (TA852)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2022
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 November 2021
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 June 2021
Balloon cryoablation for squamous dysplasia of the oesophagus (IPG683)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 October 2020
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus (IPG497)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 July 2014
Minimally invasive oesophagectomy (IPG407)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 September 2011
Endoscopic submucosal dissection of oesophageal dysplasia and neoplasia (IPG355)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 September 2010
Palliative photodynamic therapy for advanced oesophageal cancer (IPG206)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 January 2007
Photodynamic therapy for early-stage oesophageal cancer (IPG200)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
13 December 2006
Oesophago-gastric cancer (QS176)
Product type:
Quality standard
Published:
13 December 2018
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC